Navigation Links
NYU Langone Medical Center's tip sheet to the International Conference on Alzheimer's Disease 2008
Date:7/25/2008

, Assistant Professor, Department of Psychiatry, NYU Langone Medical Center; Research Scientist, Center for Dementia Research, Nathan S. Kline Institute
EMBARGOED FOR RELEASE UNTIL SUNDAY, JULY 28, 2008 at 3:00 p.m. CT

By manipulating levels of the beta amyloid peptide, which accumulates in brain plaques in people with Alzheimer's disease, NYU researchers have found that the peptide not only plays a toxic role in the neurodegenerative disease but also is crucial in modulating learning and memory consolidation in the normal brain. The rat study, which controlled peptide levels in a region of the brain that is important in learning and memory, suggests that its disruption may be one of the underlying causes of nerve dysfunction during Alzheimer's disease pathogenesis.
Presentation #02-02-01

Dysfunctional Transporters in Nerves Related to Alzheimer's
Seonil Kim, Ph.D student, Sackler Institute for Graduate Biomedical Sciences, NYU Langone Medical Center, Graduate Training Program in Cellular and Molecular Biology, Nathan S. Kline Institute and Ralph Nixon, M.D., Ph.D., Professor of Psychiatry and Cell Biology, NYU Langone Medical Center
EMBARGOED FOR RELEASE UNTIL TUESDAY, JULY 29, 2008 at 12:30 p.m. CT

An NYU study found that membrane vesicles that are essential for the trafficking of materials across nerve cells are an important factor in the pathology of Alzheimer's disease. Mouse neurons which over-produce a precursor to the amyloid protein closely linked to Alzheimer's disease development were unable to shuttle the vesicles to their proper destinations in nerve cells, causing them instead to enlarge abnormally and accumulate. The impeded transport of these vesicles, according to the researchers, may affect communications within and between nerve cells that are critical for cognition and when disrupted can lead to the neurodegeneration of Alzheimer's disease.
Presentation # PS-410

'/>"/>

Contact: Bob Brody
bobbrody@hotmail.com
212-404-3555
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

7

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 1Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 1Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 3Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 4Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 5Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 6Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 7Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 8Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 9Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 10Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 11Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 12Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 13Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 14Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 15Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 16Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 17Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 18Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 19Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 20Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 21Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 22Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 23Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 24Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 25Omnetics Announces Newest Addition to Nano Circular Family 62401 1Omnetics Announces Newest Addition to Nano Circular Family 62401 2
Other Biology Technology:The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 2The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 3The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 4The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 5The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 6The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 2Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 3Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 4Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 6Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 7Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 8Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 9Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 10